German prices negotiated with sick funds remain confidential under AMNOG Novelle

Dear All,

as the Deutsche Apothekerzeitung reports, the prices that manufacturers negotiate with association of sick funds (GKV Spitzenverband) after the IQWIG benefit assessment will stay confidential and will not be published in the Lauer Taxe. This is the compromise that now seems to have been reached after long discussions of the AMNOG Novelle. The vfa (Verband forschender Arzneimittelhersteller) commented that confidentiality does not mean secrecy and that private insurers and importers should know about. That would be good news for the pharmaceutical industry as the negative downward pressures on prices due to international price referencing might be avoided.


1 comment:

Unknown said...

Hi Ulf! I am happy to be here and to read more about health economics from your blog. I am new to the field, and was browsing around the internet for more information on it. I am due to begin a master's degree in health economics this September. I look forward to learning more and becoming an active professional in this field. So far I am extremely amazed and impressed at the scope and ken covered by health economics. I am quite excited about it and very eager to begin learning and practicing. Thank you!

Nairobi, Kenya